Ibopamine 2% eye drops in the treatment of patients with ocular hypotony after vitreoretinal surgery for retinal detachment or uveitis: results after six months of treatment

Submission date	Recruitment status No longer recruiting	Prospectively registered		
20/12/2005		☐ Protocol		
Registration date 20/12/2005	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
12/04/2021	Eve Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr J C van Meurs

Contact details

Oogziekenhuis Rotterdam Schiedamsevest 180 Rotterdam Netherlands 3011 BH +31 (0)10 401 7777 vanMeurs@oogziekenhuis.nl

Additional identifiers

Protocol serial number OZR-2003-16

Study information

Scientific Title

Ibopamine 2% eye drops in the treatment of patients with ocular hypotony after vitreoretinal surgery for retinal detachment or uveitis: results after six months of treatment

Study objectives

Long-term administration of Ibopamine hydrochloride eye drops restores and maintains intraocular pressure in patients with hypotony following vitreoretinal surgery for ablatio reinae, or uveitis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Non-randomised trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Ocular hypotony following either vitreoretinal surgery or uveitis

Interventions

Long-term topical treatment with Ibopamine (2%) eye drops.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Ibopamine

Primary outcome(s)

- 1. Ocular pressure
- 2. Vision

Key secondary outcome(s))

- 1. Position of silicone oil (after surgery)
- 2. Patients comfort/pain five minutes after eye drops administration

Completion date

01/03/2006

Eligibility

Key inclusion criteria

- 1. Hypotony (0-5 mm Hg)
- 2. Stable eye pressure for at least 4 months
- 3. No reaction of eye pressure to atropine and steroids
- 4. Continued steroid treatment during past six months
- 5. Status after vitreoretinal surgery or uveitis

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

All

Total final enrolment

17

Key exclusion criteria

- 1. Chronic heart failure
- 2. Hypotony caused by other factors than surgery or uveitis
- 3. Traction on corpus ciliare
- 4. Cyclodialysis

Date of first enrolment

01/03/2004

Date of final enrolment

01/03/2006

Locations

Countries of recruitment

Netherlands

Study participating centre Oogziekenhuis Rotterdam

Rotterdam Netherlands 3011 BH

Sponsor information

Organisation

Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)

ROR

https://ror.org/02hjc7j46

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Foundation of Scientific Research at the Eye Hospital (Stichting Wetenschappelijk Onderzoek het Oogziekenhuis) (The Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		01/04/2012	12/04/2021	Yes	No